信必可都保吸入对中重度COPD患者的疗效观察

目的观察信必可都保（4．5／160μg）在慢性阻塞性肺疾病（COPD）缓解期中的疗效。方法确诊的中、重度COPD患者42例，随机分为治疗组和对照组。对照组给予氨茶碱片0．1g，tid，万托林1喷／次，tid；治疗组给予吸入信必可都保（4．5／160μg）1喷／次，bid。结果治疗组在观察期间患者临床症状、肺功能较对照组显著改善，急性发作次数显著低于对照组。结论在中、重度COPD缓解期中使用信必可都保能提高患者肺功能，显著改善患者症状，并减少急性发作的频率。

Efficacy Observation on Inhalation Treatment with Symbicort Tu Rbuhaler Inhalation for Cases of Moderate and Severe COPD

Objective To observe the effects of Symbicort Tu Rbuhaler（budesonide and formoterolfum arate）powder inhalants（4.5/160μg）in chronic obstructive pulmonary disease （COPD）during the mitigation. Methods In the treatment of moderate and severe 42 patients with COPD in the department of respiratory diseases in our hospital,the patients were randonfly divided into treatment and control group.The control group was given Aminophylline Tablets 0.t,tid, and Salbutarnol Aerosol 2-3 puff, tid, while the treatment group was given the aspiration for Symbicort Tu Rbuhaler（4.5/160ug）, 1 puff, bid. Results During the period of observation, the clinical symptom and lung function were significantly improved more than those of the control group（0.05）,meanwhile the number of acute exacerbation of COPD was obviously lower than the control group. Conclusions Seretide in the treatment of moderate and severe COPD during the mitigation can reduce the number of acute exacerbation of COPD, enhance patients with lung function, and has obvious improvement of their clinical symptom.